Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,738
datasets available to search
ShareScore release 0.9.0
Dataset results
2,738 results for “Multiple sclerosis”
Twin study identifies early immunological and metabolic dysregulation of CD8+ T cells in multiple sclerosis
GEO Series GSE276167. Homo sapiens. 2 samples. Type: Expression profiling by high throughput sequencing.
A novel animal model for secondary progressive multiple sclerosis by oligodendroglia-specific conditional connexin 47 knockout [Agilent]
GEO Series GSE121335. Mus musculus. 8 samples. Type: Expression profiling by array.
Microarray analysis of Multiples Sclerosis Brain tissue in comparison to control brain tissue
GEO Series GSE5839. Homo sapiens. 4 samples. Type: Expression profiling by array.
Data for: Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
<p>Protein levels were measured in cerebrospinal fluid samples (CSF; n = 186) and plasma samples (n = 165) from persons with multiple sclerosis and healthy controls. CSF samples and plasma samples were taken from 92 persons with CIS or RRMS at Linköping University Hospital, Sweden and 51 persons with CIS or RRMS at the Karolinska University Hospital, Sweden. Everyone fulfilled the revised McDonald criteria from 2010 and 2017 for CIS or Multiple sclerosis (MS). Age-matched healthy controls (HC) were recruited from healthy blood donors (23 at the Linköping University hospital and 20 at the Karolinska University Hospital). The concentration of 1463 proteins were measured using the Olink Explore platform which uses Proximity Extension Assay (PEA) technology. The proteins were preselected from four Olink panels: Explore 384 Cardiometabolic, Explore 384 Inflammation, Explore 384 Neurology, and Explore 384 Oncology. The protein concentrations are given as Olink’s relative protein quantification unit on log2 scale: Normalized Protein Expression (NPX). The NPX values were intensity normalized by Olink.</p>
Dataset related to article "Gamma Knife Radiosurgery for the Treatment of Trigeminal Neuralgia in Patients with Multiple Sclerosis: A Single-Center Retrospective Study and Literature Review" "
<p>This record contains raw data related to article “Gamma Knife Radiosurgery for the Treatment of Trigeminal Neuralgia in Patients with Multiple Sclerosis: A Single-Center Retrospective Study and Literature Review"</p> <p><strong>Objective: </strong> Trigeminal neuralgia (TN) in patients with multiple sclerosis (MS) is a challenging condition to manage that is treated with Gamma Knife radiosurgery (GKRS). The aim of this report is to assess the safety, efficacy, and durability of GKRS for the treatment of TN in patients with MS. Our findings are compared with those of the existing literature and discussed.</p> <p><strong>Methods: </strong> We retrospectively reviewed all patients at our institution who underwent GKRS for the treatment of TN secondary to MS and had 1 or more years of follow-up. Preoperative and postoperative pain intensities and facial numbness were evaluated with the Barrow Neurological Institute scores. Durability of successful pain relief was statistically evaluated with Kaplan-Meier analysis. The prognostic role of perioperative factors was investigated and analyzed using Cox proportional hazards regression.</p> <p><strong>Results: </strong> There were 29 patients with MS-TN who underwent GKRS at our institution. Two patients underwent bilateral treatment. Four patients underwent repeat GKRS for pain recurrence. The median period of follow-up assessment was 33 months. Rates of reasonable pain reduction at 1, 3, and 5 years were 70%, 57%, and 57% respectively. All patients who underwent repeat GKRS had durable pain reduction. No prognostic factor for successful pain reduction was found.</p> <p><strong>Conclusions: </strong> Our study shows that GKRS for the treatment of TN secondary to MS is a safe and effective procedure in controlling pain in the short term but often fails to provide long-term pain control. GKRS can be safely repeated to prolong the time of pain reduction.</p>
Dataset related to article "Effectiveness of a group resilience intervention for people with multiple sclerosis delivered via frontline services"
<p>This study is part of a broader multi-phased project designed to comprehensively evaluate an Acceptance and Commitment Therapy-based group resilience intervention (The REsilience and Activities for every DaY program, READY) for people with MS in Italy.</p> <p>The project encompasses two major phases: (1) a pilot randomized controlled trial (RCT) with a nested qualitative study; (2) a multi-centre phase III cluster RCT (ISRCTN registration number: 67194859), with an ancillary study on the effectiveness of a program for training psychologists in the delivery of READY to PwMS.</p> <p>The data support the findings of the study: “Effectiveness of a group resilience intervention for people with multiple sclerosis delivered via frontline services”. For this study, data were collected on voluntary based by psychologists involved in the training (phase three – delivery of READY in frontline service), immediately before the program, after the booster session, and at 3-months follow-up.</p> <p>They include demographic and clinical data, ant items of the patient-reported outcome measures administered.</p>
Increased concentrations of P2X7R in oligodendrocyte derived extracellular vesicles of Multiple sclerosis patients
<p>Dataset associated with paper "Increased concentrations of P2X7R in oligodendrocyte derived extracellular vesicles of Multiple sclerosis patients".</p> <p>This set of raw data cannot be made publicly available as including sensitive information, but might be made available to interested researchers upon reasonable request. Please, forward you request to fguerini@dongnocchi.it.</p>
Single cell sequencing data of PBMC and CSF from a cohort of Multiple Sclerosis patients and other neurological disease controls
<p><span>Neuroinflammation is often characterised by immune cell infiltrates in the cerebrospinal fluid (CSF). Here we apply single-cell RNA sequencing to explore the functional characteristics of these cells in patients with various inflammatory, infectious and non-inflammatory neurological disorders. We show that CSF is distinct from the peripheral blood in terms of both cellular composition and gene expression. We report that the cellular and transcriptional landscape of CSF is altered in neuroinflammation, but is strikingly similar across different neuroinflammatory disorders. We find clonal expansion of CSF B and T cells in all disorders but most pronounced in inflammatory diseases, and we functionally characterise the transcriptional features of these cells. Finally, we explore the genetic control of gene expression in CSF lymphocytes. Our results highlight the common features of immune cells in the CSF compartment across diverse neurological diseases and may help to identify new targets for drug development or repurposing in Multiple Sclerosis. </span></p> <p><span>This dataset contains a tarball with six files:</span></p> <ul> <li><span>A Seurat object with 5' single-cell gene expression data for all cells in the dataset</span></li> <li><span>A Seurat object with B cells only, containing 5' single-cell gene expression data and VDJ data in the metadata</span></li> <li><span>A Seurat object with T cells only, containing 5' single-cell gene expression data and VDJ data in the metadata</span></li> <li><span>Separate .csv files with the metadata alone for each of the three datasets</span></li> </ul> <p><span>These data have undergone very light quality control and contain only the raw, non-normalised RNA counts in the RNA assay (adjusted only for ambient RNA contamination). Details of QC steps used in the paper are given in the github. Please note that these data were generated across two sites and across multiple batches, and so any analysis should account for this potential source of technical variability. Metadata include the following key columns:</span></p> <ul> <li><span>batch_id: the batch </span></li> <li><span>source: whether the sample is from CSF or PBMC</span></li> <li><span>processing_site: whether the sample was processed in Munich or Cambridge</span></li> <li><span>Category: the diagnostic group (MS, Other Inflammatory Neurological Disease, Other Inflammatory Neurological Disease - Infection, and Non-inflammatory Neurological Disease)</span></li> <li><span>Sex</span></li> <li><span>OCB: whether the patient had CSF oligoclonal bands </span></li> <li><span>fully_anonymous_pseudoid: donor ID</span></li> <li><span>ann_celltypist_lowres: automated cell type assigment at low res </span></li> <li><span>ann_celltypist_highres: automated cell type assigment at high res</span></li> </ul> <p><span>VDJ datasets (B and T cells) contain many additional metadata columns with information on the VDJ and VJ transcripts expressed by each cell. </span></p>
ABNORMAL MULTISENSORY INTEGRATION IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
<p>Dataset of the paper "ABNORMAL MULTISENSORY INTEGRATION IN RELAPSING-REMITTING MULTIPLE SCLEROSIS"</p>
Data platform related to ERDF postdoctoral project No. 1.1.1.2/VIAA/4/20/718 "The role of vitamin D gene polymorphisms and its receptors in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis".
<p><strong>Description of contents of the data platform (dataset 1 ) based on the ERDF postdoctoral project No. 1.1.1.2/VIAA/4/20/718</strong><strong> “</strong><strong>The role of vitamin D and its receptor gene polymorphisms in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis</strong><strong>”. </strong></p> <p><strong>About the project and gathered data:</strong></p> <p>The two datasets contain clinical data on 289 sex-balanced samples (approximately 60% women / 40% men)) were created at the MS Clinic of the Latvian Maritime Medical Center (LMMC) in 2011 (disease duration of 1-51 years); the collection was updated within the framework of the ERDF MS project (2017-2020) and replenished during the ERDF postdoctoral project No. 1.1.1.2/VIAA/4/20/718 “The role of vitamin D and its receptor gene polymorphisms in the modulation of intestinal inflammation in patients with relapsing and progressive forms of multiple sclerosis” (2021-2023).</p> <p>The following pre-selected information was assessed from the clinic database for each patient for the <strong>first dataset (1 Data_MS collection)</strong>: gender, age, age of onset of multiple sclerosis (MS), year of onset, the first symptoms, exacerbations in the first year, clinical MS disease course (estimated Expanded Disability Status Scale (EDSS) at diagnosis, Disease-Modifying Therapy (DMT), clinical activity, Magnetic resonance (MR) activity, other autoimmune diseases, duration of illness, time of the transition from relapsing-remitting MS course (RRMS) to secondary-progressive MS course (SPMS); year of start SPMS, RRMS>SPMS (RRMS duration in years). Clinical information was distributed according to the development of disease progression over five visits. Information related to the forms of disability progression of MS was assessed from medical files for the given period (12 years) for a complete picture of the history of disease progression.</p> <p>The following pre-selected information was assessed from the clinic database for each patient for the first dataset <strong>(</strong><strong>2 </strong><strong>Data_MS_2011_2018_2022):</strong> <strong>Clinical</strong> <strong>data for 2011:</strong> Age, clinical course of MS, estimated Expanded Disability Status Scale (EDSS)<strong>,</strong> Clinical activity, Invalidity progression, MR activity, NEDA-3*, IgA, g/l, IgM, g/l, IgG, g/l, CD3, cell/ml, CD4, cell/ml, CD8, cell/ml, Disease-Modifying Therapy (DMT), period of therapy.</p> <p>*Progress of disease and response to treatment was evaluated in terms of “no evidence of disease activity” (NEDA) standard (Stangel, 2015) measured by relapses, progression of disability and new and/or enlarging demyelinating lesions as seen on MRI.</p> <p><strong>Updated data for 2018</strong>: Duration of illness, clinical course of MS, EDSS</p> <p><strong>Updated data</strong> <strong>for 2020-22 years:</strong> EDSS 2020 and EDSS 2022, CRP (ug/mL), µg/ml, 25-OH-Vitamin D (ng/mL), Total IgE (IU/mL), Endotoxin (LPS), EU/m, Human LBP (ng/mL), EndoCab IgA, AMU/ml, EndoCab IgG, GMU/ml, EndoCab IgG, GMU/ml.</p>
Deep cervical lymph nodes of patients with multiple sclerosis show dysregulated B cells in the presence of Epstein-Barr virus2
<p>5´ scRNAseq data including TCR and BCR-seq data and CITE-seq data to reproduce the findings in the manuscript "Deep cervical lymph nodes of patients with multiple sclerosis show dysregulated B cells in the presence of Epstein-Barr virus". <br><br>The folder contains Seurat objects:</p><ul><li>msFNA_allData.rds (scRNAseq data)</li><li>msFNA_withBCR_Data.rds (BCR-seq data)</li><li>msFNA_withTCR_Data.rds (TCR-seq data)</li><li>msFNA_withCiteseq_Data.rds (CITE-seq data)</li></ul><p> </p>
Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies
ClinicalTrials.gov study NCT01020370. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
ClinicalTrials.gov study NCT04540861. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up
ClinicalTrials.gov study NCT00289159. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Transcriptomic analyses of normal-appearing CNS white matter from multiple sclerosis donors reveal subtype-specific molecular signatures of disease
GEO Series GSE214334. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing.
A single-cell resolution spatial transcriptomics atlas of human multiple sclerosis lesion (MERSCOPE)
GEO Series GSE284005. synthetic construct; Homo sapiens. 17 samples. Type: Other.
Single-cell spatial transcriptomic profiling defines a pathogenic inflammatory niche in chronic active multiple sclerosis lesions - Microglia cell culture
GEO Series GSE301696. Mus musculus; synthetic construct. 4 samples. Type: Other.
miRNAs in extracellular vesicles prepared from patients with multiple sclerosis
GEO Series GSE86863. Homo sapiens. 8 samples. Type: Non-coding RNA profiling by array.
Inhibition of astrocytic DRD2 suppresses CNS inflammation in an animal model of multiple sclerosis [astrocyte]
GEO Series GSE205290. Mus musculus. 4 samples. Type: Expression profiling by array.
Inhibition of astrocytic DRD2 suppresses CNS inflammation in an animal model of multiple sclerosis
GEO Series GSE205292. Mus musculus. 16 samples. Type: Expression profiling by array; Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.